BACKGROUND:Markers of collagen type I (CTX-1) and type II (CTX-II) degradation, reflecting bone and cartilage breakdown, appear to predict long term radiographic progression in chronic persistent arthritis. OBJECTIVE: To analyse longitudinally whether changes in arthritis severity are linked to immediate changes in the level of CTX-I and CTX-II degradation. METHODS:CTX-I and CTX-II were measured in urine samples from 105 patients with early rheumatoid arthritis who had participated in the COBRA trial at baseline and at 3, 6, 9, and 12 months after the start of treatment. The course of the biomarkers over time was compared with the course of ESR, swollen and tender joint counts, and 28 joint disease activity score (DAS28), measured at the same time points, with adjustment for rheumatoid factor, treatment, and baseline radiographic damage, by generalised estimating equations (GEE) with first order autoregression. RESULTS: GEE showed that CTX-I was longitudinally associated with DAS28, but not with ESR, swollen joint count, or tender joint count. CTX-II, however, was longitudinally associated with ESR, swollen joint count and DAS28, but not with tender joint count. The longitudinal association implies that an increase in the extent of arthritis is immediately followed by an increase in collagen type II degradation, and to a lesser extent collagen type I degradation. CONCLUSIONS:Cartilage degradation as measured by CTX-II and to a lesser extent bone degradation as measured by CTX-I closely follows indices of arthritis. Clinically perceptible arthritis is responsible for immediate damage, which will become visible on plain x rays only much later.
RCT Entities:
BACKGROUND: Markers of collagen type I (CTX-1) and type II (CTX-II) degradation, reflecting bone and cartilage breakdown, appear to predict long term radiographic progression in chronic persistent arthritis. OBJECTIVE: To analyse longitudinally whether changes in arthritis severity are linked to immediate changes in the level of CTX-I and CTX-II degradation. METHODS: CTX-I and CTX-II were measured in urine samples from 105 patients with early rheumatoid arthritis who had participated in the COBRA trial at baseline and at 3, 6, 9, and 12 months after the start of treatment. The course of the biomarkers over time was compared with the course of ESR, swollen and tender joint counts, and 28 joint disease activity score (DAS28), measured at the same time points, with adjustment for rheumatoid factor, treatment, and baseline radiographic damage, by generalised estimating equations (GEE) with first order autoregression. RESULTS: GEE showed that CTX-I was longitudinally associated with DAS28, but not with ESR, swollen joint count, or tender joint count. CTX-II, however, was longitudinally associated with ESR, swollen joint count and DAS28, but not with tender joint count. The longitudinal association implies that an increase in the extent of arthritis is immediately followed by an increase in collagen type II degradation, and to a lesser extent collagen type I degradation. CONCLUSIONS: Cartilage degradation as measured by CTX-II and to a lesser extent bone degradation as measured by CTX-I closely follows indices of arthritis. Clinically perceptible arthritis is responsible for immediate damage, which will become visible on plain x rays only much later.
Authors: M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden Journal: Lancet Date: 1997-08-02 Impact factor: 79.321
Authors: Robert B M Landewé; Maarten Boers; Arco C Verhoeven; Rene Westhovens; Mart A F J van de Laar; Harry M Markusse; J Christiaan van Denderen; Marie Louise Westedt; Andre J Peeters; Ben A C Dijkmans; Piet Jacobs; Annelies Boonen; Désirée M F M van der Heijde; Sjef van der Linden Journal: Arthritis Rheum Date: 2002-02
Authors: Patrick Garnero; Robert Landewé; Maarten Boers; Arco Verhoeven; Sjef Van Der Linden; Stephan Christgau; Désirée Van Der Heijde; Annelies Boonen; Piet Geusens Journal: Arthritis Rheum Date: 2002-11
Authors: M A van Leeuwen; M H van Rijswijk; W J Sluiter; P L van Riel; I H Kuper; L B van de Putte; M B Pepys; P C Limburg Journal: J Rheumatol Date: 1997-01 Impact factor: 4.666
Authors: Paco M J Welsing; Robert B M Landewé; Piet L C M van Riel; Maarten Boers; Anke M van Gestel; Sjef van der Linden; Hilde L Swinkels; Désirée M F M van der Heijde Journal: Arthritis Rheum Date: 2004-07
Authors: Robert Landewé; Piet Geusens; Maarten Boers; Désirée van der Heijde; Willem Lems; Johan te Koppele; Sjef van der Linden; Patrick Garnero Journal: Arthritis Rheum Date: 2004-05
Authors: M A van Leeuwen; M H van Rijswijk; D M van der Heijde; G J Te Meerman; P L van Riel; P M Houtman; L B van De Putte; P C Limburg Journal: Br J Rheumatol Date: 1993-06
Authors: Sophie Aschenberg; Stephanie Finzel; Sarah Schmidt; Sebastian Kraus; Klaus Engelke; Matthias Englbrecht; Jürgen Rech; Georg Schett Journal: Arthritis Res Ther Date: 2013 Impact factor: 5.156
Authors: Arno W R van Kuijk; Jeroen DeGroot; Rishma C Koeman; Nico Sakkee; Dominique L Baeten; Danielle M Gerlag; Paul P Tak Journal: PLoS One Date: 2010-09-03 Impact factor: 3.240
Authors: Morten A Karsdal; Thasia Woodworth; Kim Henriksen; Walter P Maksymowych; Harry Genant; Philippe Vergnaud; Claus Christiansen; Tanja Schubert; Per Qvist; Georg Schett; Adam Platt; Anne-Christine Bay-Jensen Journal: Arthritis Res Ther Date: 2011-04-28 Impact factor: 5.156
Authors: Marije F Bakker; Suzanne M M Verstappen; Paco M J Welsing; Johannes W G Jacobs; Zalima N Jahangier; Maaike J van der Veen; Johannes W J Bijlsma; Floris P J G Lafeber Journal: Arthritis Res Ther Date: 2011-05-08 Impact factor: 5.156
Authors: Josef S Smolen; Daniel Aletaha; Johannes Grisar; Kurt Redlich; Günter Steiner; Oswald Wagner Journal: Arthritis Res Ther Date: 2008-05-29 Impact factor: 5.156